Successful patent challenges hinder innovation in pharmaceutical industry

Hasson, Matt
December 2009
Ocular Surgery News;12/10/2009, Vol. 27 Issue 23, p45
Academic Journal
The article discusses research on the link between drug patent challenges and a decline in prescription drug innovation and development since the enactment of a U.S. federal law a quarter century ago. It references a study by Stuart Graham and Matthew J. Higgins, published in "Science." The researchers examined the implications of the Drug Price Competition and Patent Term Resolution Act of 1984.


Related Articles

  • Patent watch. Harrison, Charlotte // Nature Reviews Drug Discovery;Nov2008, Vol. 7 Issue 11, p882 

    The article reports on the injuction granted by the U.S. District Court to the drug for anemia, Mircera, by Amgen Inc. Balance of three factors, namely patient health, Medicare factors and patent system of Amgen's competitors, according to the authors, are also examined by the court....

  • THE HEALTH IMPACT FUND PROPOSAL: APPLICATION IN THE UNITED STATES' ERA OF COMPARATIVE EFFECTIVENESS. Racz, Katherine Jeanne // Journal of Intellectual Property Law;Spring2012, Vol. 19 Issue 2, p487 

    The article explores the failures of the traditional U.S. patent system regarding pharmaceuticals in order to improve the quality and to decrease the costs of pharmaceuticals. It informs about the Health Impact Fund (HIF) which is a revolutionary solution to benefit the consumers by decreasing...

  • STAKEHOLDER PERSPECTIVE: Orphan Drugs: The Potential Impact of Generic Biologics. Nair, Kavita V. // American Health & Drug Benefits;Jan2010, Vol. 3 Issue 1, p22 

    The article discusses the entry of generic biologics into the U.S. marketplace, and the potential impact. Legislation has been proposed by Rep. Henry Waxman, and the Obama administration that would allow brand-name biologics used for orphan drugs to be subject to competition from generics after...

  • Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act. Grabowski, Henry G.; Kyle, Margaret; Mortimer, Richard; Long, Genia; Kirson, Noam // Health Affairs;Nov2011, Vol. 30 Issue 11, p2157 

    The evolution of pharmaceutical competition since Congress passed the Hatch-Waxman Act in 1984 raises questions about whether the act's intended balance of incentives for cost savings and continued innovation has been achieved. Generic drug usage and challenges to brand-name drugs' patents have...

  • Oversight in U.S. is effective. Coopman, Robert // Chain Drug Review;1/7/2013, Vol. 35 Issue 1, p84 

    The article discusses the effectiveness of oversight by the U.S. Food and Drug Administration (FDA) in protecting patients and intellectual property via a rigorous medication patent approval process. Topics include the cost of such processes and protections, why private or public enterprises...

  • Prop. 61 Can Set National Model. DeMoro, RoseAnn // National Nurse;May/Jun2016, Vol. 112 Issue 3, p13 

    The article offers information on the importance of Prop. 61, a drug price standards initiative which aims to lower drug prices in the U.S. Topics mentioned include the increase in the average price of brand-name drugs in the country, the impact of predatory pricing on state governments, and...

  • Reconsidering the U.S. Patent System: Lessons from Generics. Chen, Molly F. M. // Vanderbilt Journal of Transnational Law;Oct2012, Vol. 45 Issue 4, p1249 

    Scholars and pharmaceutical industry representatives consider the United States a worldwide leader in pharmaceutical innovation. However, the recent expansion of the international generics market has threatened the strength of the U.S. pharmaceutical industry. The pressure has led to the U.S....

  • Missouri lawmakers give state's phanmacy board authority over veterinary legend drugs.  // DVM: The Newsmagazine of Veterinary Medicine;Sep2011, Vol. 42 Issue 9, p42 

    The article focuses on the new U.S. Senate Bill 325 which is giving authority to the state pharmacy board for retailing veterinary legend drugs.

  • Expanding category requires extra care.  // Chain Drug Review;1/3/2011, Vol. 33 Issue 1, p64 

    The article discusses a study conducted by the Center for Healthcare Supply Chain Research in Arlington, Virginia, which suggests that the government needs to be careful for creating intravenous medications-related regulations.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics